Observational studyThe Laryngoscope2025
Neck Active Monitoring After Partial Laryngectomy for cT2N0M0 True Vocal Cord SCC: A 10-Year STROBE Analysis.
Observational study in The Laryngoscope, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Neck Active Monitoring After Partial Laryngectomy for cT2N0M0 True Vocal Cord SCC: A 10-Year STROBE Analysis.The Laryngoscope · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate 10-year nodal outcome of active monitoring of the neck for cT2N0M0 true vocal cord (TVC) squamous cell carcinoma (SCC) after frontline partial laryngectomy (PL). STUDY
designRetrospective observational study adhering to the STROBE guideline.
settingFrench academic tertiary referral care center. PATIENTS: Inception cohort of 81 isolated and untreated cT2N0M0 TVC SCC consecutively managed between 1983 and 2013 with frontline PL and active monitoring of the neck. 85% of patients were followed until death or for at least 10 years.
main outcome measuresMain endpoint was 10-year actuarial nodal control analysis. Secondary endpoints were the search for potential variables increasing the risk for nodal recurrence, management of nodal recurrence, and analysis of the oncologic consequences of nodal recurrence. The significance threshold was set at p < 0.005.
resultsThe 10-year actuarial nodal control estimate was 90% with salvage treatment, yielding a 99% overall nodal control rate. On univariate analysis, none of the variables assessed significantly statistically increased the risk for nodal recurrence. The 10-year actuarial estimate of distant metastasis was 0% in patients with nodal control as compared with 35% in patients with nodal recurrence (p < 0.0001). The 10-year actuarial survival estimate was 0% in patients with nodal recurrence as compared with 67% in patients with nodal control (p < 0.0001). Among the 37 patients who died, uncontrolled SCC was the cause of death in 33% of patients who had a nodal recurrence and 3% of those who did not.
conclusionActive monitoring of the neck for cT2N0M0 TVC SCC managed with PL, although not detrimental in terms of overall nodal control, is impaired by the negative oncological impact of nodal recurrence. LEVEL OF EVIDENCE: 4:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.